Kazia Therapeutics Limited (KZIA)
- Previous Close
0.3648 - Open
0.3728 - Bid 0.3702 x 100
- Ask 0.3850 x 100
- Day's Range
0.3570 - 0.3890 - 52 Week Range
0.1900 - 1.3900 - Volume
55,547 - Avg. Volume
839,428 - Market Cap (intraday)
9.754M - Beta (5Y Monthly) 2.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7300 - Earnings Date Mar 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.99
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
www.kaziatherapeutics.comRecent News: KZIA
Performance Overview: KZIA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KZIA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KZIA
Valuation Measures
Market Cap
9.75M
Enterprise Value
7.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.25
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.42%
Return on Equity (ttm)
-186.37%
Revenue (ttm)
560
Net Income Avi to Common (ttm)
-15.7M
Diluted EPS (ttm)
-0.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.56M
Total Debt/Equity (mrq)
6.82%
Levered Free Cash Flow (ttm)
-6.57M